Background
==========

Skin cutaneous melanoma (SKCM) is the most aggressive skin tumor and the main cause of skin cancer death \[[@b1-medscimonit-26-e923087]\]. Its incidence is growing faster than any of the top 10 cancers \[[@b2-medscimonit-26-e923087]\].The prognosis of SKCM remains tremendously poor, and only 15--20% of patients with distance metastases survive for 5 years after diagnosis \[[@b3-medscimonit-26-e923087]\]. Obvious geographical regional differences have been shown in the incidence characteristics of SKCM. Among the Asian Eastern populations, the incidence of SKCM occurs mostly at the extremities, and the V-raf murine sarcoma viral oncogene homolog (BRAF) gene mutation rate is about 24.3% \[[@b4-medscimonit-26-e923087]\]. While in the Caucasian Western populations, it is more common in the head and face \[[@b5-medscimonit-26-e923087]\], and the BRAF gene mutation rate about 50% \[[@b6-medscimonit-26-e923087]\]. Some genes and their effects have been shown to be related to SKCM and its metastasis, such as the chemokine C-X-C receptor 4 (CXCR4) gene silencing of melanoma invasion and metastasis \[[@b7-medscimonit-26-e923087]\], the promotion of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways on the progression of SKCM \[[@b8-medscimonit-26-e923087]\], and the prediction of distant metastasis by serum lactate dehydrogenase (LDH) \[[@b9-medscimonit-26-e923087]\]. However, there are still no promising biomarkers to predict prognosis and treatment, especially immunotherapy in SKCM. Therefore, it is meaningful to explore novel biomarkers at the molecular level.

T-box transcription factor protein 21 (TBX21) is one of the T-box family and TBX21 is a specific transcription factor for T helper 1 (Th1) cell transformation which regulates the expression of interferon gamma (IFNG) and the hallmark Th1 cytokine interferon \[[@b10-medscimonit-26-e923087],[@b11-medscimonit-26-e923087]\]. TBX21 contains 530 amino acids and has an open reading frame of about 1607 bp in length. Among them, there is a 189 amino acid-containing domain that can bind to T-box DNA (i.e., T-site). This region is highly conserved and can be combined with the corresponding DNA sequence to perform its function. TBX21 is located on human chromosome 17 and mouse chromosome 11. Extensive evidence has suggested that TBX21 is associated with cancer progression such as esophageal cancer \[[@b12-medscimonit-26-e923087]\], lung cancer \[[@b13-medscimonit-26-e923087]\], etc., by regulating a host's immune response. However, few studies have reported on the expression and role of TBX21 in SKCM. It is of urgent need to elucidate the expression, prognosis, and mechanism of TBX21 in the development of SKCM.

Material and Methods
====================

Patient datasets
----------------

The clinical data and gene expression profiles of SKCM patients and normal controls in this paper are mainly derived from The Cancer Genome Atlas (TCGA) (*<https://portal.gdc.cancer.gov/>*) and the Genotype-Tissue Expression (GTEx) (*<https://toil.xenahubs.net/download/GTEX_phenotype.gz>*) datasets on 09-30-2019. TCGA-SKCM and GTEx gene expression data were analyzed by same library preparation and sequencing platform for the minimized potential batch effects and previous studies have successfully compared gene expression data from TCGA and GTEx \[[@b14-medscimonit-26-e923087]--[@b18-medscimonit-26-e923087]\]. Excluding SKCM patients with loss or follow-up time \<90 days, a total of 445 patients (all from TCGA) and 813 normal controls (1 from TCGA and the rest from GTEx) were statistically analyzed for follow-up ([Table 1](#t1-medscimonit-26-e923087){ref-type="table"}).

Gene set enrichment analysis (GSEA) and protein-protein interaction (PPI)
-------------------------------------------------------------------------

Using GSEA, we first generated an orderly gene list according to the correlation between all genes and TBX21 expression, and then identified the significant survival difference between high TBX21 group and low TBX21 group through GSEA. There were 1000 genome permutations per analysis. The expression level of TBX21 was used as a phenotype marker. Nominal *P*-value and normalized enrichment score (NES) were used to rank the enriched pathways in each phenotype. Then we analyzed the protein-protein interaction (PPI) network of TBX21 through the STRING v11.0 database, and selected interaction score \>0.4 to extract PPI for TBX21.

Statistical analysis
--------------------

R (v.3.6) was used in all statistical analysis. Wilcoxon test and logistic regression were utilized to explore the relevance between TBX21 and clinical factors. Cox regression and Kaplan-Meier method were conducted to compare the effect of TBX21 expression and other clinical characteristics on survival. The cutoff value of TBX21 expression was determined by its median value.

Results
=======

Patient characteristics
-----------------------

Basic information of 445 SKCM patients from TCGA used for analysis is summarized in [Table 1](#t1-medscimonit-26-e923087){ref-type="table"}, of which 228 patients were 58 years old or older and 217 were less than 58 years old (median age was 58 years old). Of the 445 SKCM patients, 62.25% were male and 37.75% were female. By the time we download the data (09-30-2019), 47.09% of patients were alive and 52.91% of patients were dead. Of the 402 cases for clinical stage, 6 cases were in stage 0 (1.49%), 77 cases were in stage I (19.15%), 130 cases were in stage II (32.34%), 169 cases were in stage III (42.04%), and 20 cases were in stage IV (4.98%). Stage Tis was found in 7 patients (1.74%), T0 in 23 patients (5.72%), T1 in 66 patients (16.42%), T2 in 76 patients (18.91%), T3 in 88 patients (21.89%), and T4 in 142 patients (35.32%). There were 21 out of 421 cases that had distant metastases and 176 out of 397 cases (44.33%) that had lymph node metastases.

Expression and distribution of TBX21 in normal human tissues
------------------------------------------------------------

The GTEx database collected thousands of autopsy samples, covering solid organ tissues, brain regions, whole blood, cell lines from the donor's blood and skin, for a total of 9783 normal samples. Analytical maps ([Figure 1](#f1-medscimonit-26-e923087){ref-type="fig"}) and box plots ([Figure 2](#f2-medscimonit-26-e923087){ref-type="fig"}) of TBX21 distribution in human normal tissues were drawn using the R language gganatogram and ggpubr software packages. [Figures 1](#f1-medscimonit-26-e923087){ref-type="fig"} and [2](#f2-medscimonit-26-e923087){ref-type="fig"} indicated that TBX21 gene expression was low in normal tissues and organs.

Differential expression of TBX21 in melanoma and normal skin tissue
-------------------------------------------------------------------

There are 33 types of cancer collected in TCGA, including a total of 9736 tumor samples, but only 726 normal samples are provided. Therefore, the analysis between tumor and normal data only based on TCGA will result in low analysis efficiency due to this imbalance. The GTEx collected gene expression sequencing data has 9783 normal samples. Meanwhile, the expression data from TCGA and GTEx are calculated under the same pipeline, so the data of GTEx and TCGA can be integrated, analyzed, and compared. By integrating normal skin samples from GTEx and TCGA databases, a total of 813 normal samples were obtained, including 812 from GTEx database and 1 from TCGA database; in addition, 471 tumor samples were obtained from TCGA. Compared with control group, TBX21 was significantly upregulated in SKCM (*P*\<0.001; [Figure 3](#f3-medscimonit-26-e923087){ref-type="fig"}).

Association with TBX21 expression and clinical factors
------------------------------------------------------

We then analyzed 445 SKCM samples from TCGA to investigate the relationship between the expression level of TBX21 and clinicopathologic variables. The related results are shown in [Figure 4A--4F](#f4-medscimonit-26-e923087){ref-type="fig"}). The expression of TBX21 was significantly correlated with clinical stage (*P*\<0.001) and T stage (*P*\<0.01). Further univariate analysis using logistic regression indicated that the expression of TBX21 was related to clinical stage (stage II versus stage I: odds ratio \[OR\]=0.4567 (0.2570--0.8031), *P*=0.0069) and T stage (T2 versus T1: OR=0.4643 (0.2053--1.0122), *P*=0.0581). These results suggested that the expression of TBX21 decreased gradually in the development of SKCM ([Table 2](#t2-medscimonit-26-e923087){ref-type="table"}).

Survival outcomes and multivariate analysis
-------------------------------------------

According to the median value of TBX21 expression, SKCM patients were divided into a high TBX21 expression group and a low TBX21 expression group. As shown in [Figure 5](#f5-medscimonit-26-e923087){ref-type="fig"}, the Kaplan-Meier survival analysis showed that SKCM patients with low TBX21 expression had a worse prognosis than those with high TBX21 expression (hazard ratio \[HR\]: 0.6911 (0.5745--0.8315); log-rank *P*=1.009e-04). Univariate Cox analysis showed the same conclusion (HR: 0.6911 (0.5745--0.8315); *P*\<0.001). And other clinical factors associated with poor overall survival (OS) included age, clinical stage, T stage, and lymph node metastasis ([Table 3](#t3-medscimonit-26-e923087){ref-type="table"}, [Figure 6A](#f6-medscimonit-26-e923087){ref-type="fig"}). Multivariate Cox analysis showed that TBX21 was an independent predictor of prognosis (HR: 0.7265 (0.6058--0.8713); *P*\<0.001), along with age, T stage, and lymph node metastasis ([Table 3](#t3-medscimonit-26-e923087){ref-type="table"}, [Figure 6B](#f6-medscimonit-26-e923087){ref-type="fig"}).

GSEA and PPI
------------

Finally, GSEA was conducted to explore the low and high expression data sets of TBX21 and identify differences in the SKCM signaling pathway. As shown in [Figure 7](#f7-medscimonit-26-e923087){ref-type="fig"} and [Table 4](#t4-medscimonit-26-e923087){ref-type="table"} for the normalized enrichment scores, the highly expressed phenotypes in TBX21 were enriched to varying degrees with various signaling pathways. From high to low: chemokine signaling pathway, cytokine-cytokine receptor interaction, natural killer cell (NK) cell mediated cytotoxicity, T cell receptor signaling pathway, JAK-STAT signaling pathway, Toll-like receptor (TLR) signaling pathway, apoptosis, B cell signaling pathway, and MAPK signaling pathway. We entered TBX21 into the STRING database to forecast PPI; the result showed that trans-acting T cell-specific transcription factor 3 (GATA3), runt-related transcription factor 3 (RUNX3), Forkhead box protein 3 (FOXP3), interleukin-17A (IL-17A), C-X-C chemokine receptor type 3 (CXCR3), IL-4, IFNG, tyrosine-protein kinase (ITK/TSK), B-cell lymphoma 6 (BCL6) protein and signal transducer and activator of transcription 4 (STAT4) were enriched in the top 10 ([Figure 8](#f8-medscimonit-26-e923087){ref-type="fig"}).

Discussion
==========

An increasing amount of research has shown that TBX21 plays a critical part in genesis and progression of tumor \[[@b19-medscimonit-26-e923087]--[@b21-medscimonit-26-e923087]\]. But the expression of TBX21 and its prognostic value on SKCM has not yet been reported. In this work, the association between the TBX21 gene and SKCM was analyzed based on TCGA and GTEx databases. The results revealed that TBX21 was overexpressed in SKCM tissues obviously and patients with increased TBX21 expression had a better prognosis. The expression level of TBX21 was an independent prognostic index along with age, T stage, and lymph nodes metastasis. M stage could be used as a prognostic factor of SKCM patients in univariate Cox analysis according to other studies \[[@b22-medscimonit-26-e923087]--[@b24-medscimonit-26-e923087]\]. In our study, M stage was not a prognostic factor of SKCM patients in both univariate and multivariate analyses. Our study only included 21 patients with positive distant metastasis, which might be the cause of the difference.

TBX21, also known as T-bet, is specifically expressed in immune cells such as Th1 cells, NK cells, and dendritic cells. Therefore, as [Figures 1](#f1-medscimonit-26-e923087){ref-type="fig"} and [2](#f2-medscimonit-26-e923087){ref-type="fig"} show, the expression of TBX21 is higher in blood, lung, small intestine, and spleen, and it is lower in skin. T-bet regulates the balance of Th1/Th2 cells \[[@b10-medscimonit-26-e923087]\]. Tumor progression including melanoma is usually linked to the shift of Th1 to Th2 \[[@b25-medscimonit-26-e923087],[@b26-medscimonit-26-e923087]\]. Increased Th2 cells produce IL-4, which further inhibits the differentiation of Th1 cells. Lee et al. reported that TBX21-deficient mice were more sensitive to tumor development due to dysfunction of immune cells such as Th1 dysfunction; restoration of TBX21 suppressed tumor growth in mice \[[@b27-medscimonit-26-e923087]\]. The recognition and clearance of tumor cells by the immune system requires increased expression of TBX21 \[[@b20-medscimonit-26-e923087],[@b28-medscimonit-26-e923087]\]. Consequently, TBX21 is overexpressed in melanoma tissue compared to normal skin sample. However, as the tumor progressed, Th2 cells and regulatory T cells gradually dominated, and TBX21 expression was suppressed \[[@b29-medscimonit-26-e923087]\].

Furthermore, we also screened TBX21-related signaling pathways in SKCM to find the potential mechanism of TBX21 regulating the development of SKCM. Most of these signaling pathways were immune-related. The occurrence of malignant tumors is known to be a long-term, multi-stage, multi-gene accumulation process, and changes in apoptosis-related genes are involved in this process. Inhibition of tumor cell apoptosis is a significant pathway of tumorigenesis, so it is an important strategy for tumor therapy to induce tumor cell apoptosis. T-bet can control the type of immunoglobulin (Ig) expressed by B cells, and the expression of T-bet can promote the production of IgG2a, IgG2b, and IgG3 and inhibit the production of IgG1 and IgE \[[@b30-medscimonit-26-e923087]\]. Chemokines, including CXCR3, are small molecule-secreted proteins that can control the directed movement of immune cells. Many studies have looked at their chemotactic properties to improve the efficacy of tumor immunotherapy \[[@b31-medscimonit-26-e923087]\]. Cytokines such as IL-4, IL-17, and IFNG regulate oncogenesis and progression of tumors by binding to the corresponding cytokine receptors on the cell surface \[[@b32-medscimonit-26-e923087]\]. The JAK-STAT and MAPK signaling pathways are important transmitters from the cell surface to the inside of the cell which regulate various cellular processes, such as growth, proliferation, and differentiation \[[@b33-medscimonit-26-e923087]--[@b35-medscimonit-26-e923087]\]. NK cell is a type of non-specific tumor cell killer without prior sensitization, which plays an important role in mediating tumor microenvironment through secreting IFNG \[[@b36-medscimonit-26-e923087]--[@b38-medscimonit-26-e923087]\]. Anti-tumor immune responses are mainly mediated by T cells, the type 1 cellular immune response is modulated by CD8+CTLs, and CD4+Th1 cells are the most important among those. T-bet is known to regulate differentiation and effector functions of Th1 and CD8+ T cells \[[@b39-medscimonit-26-e923087]\]. Toll-like receptor (TLR) activates a variety of immune cells through different recognition pathways, initiates non-specific immune responses and stimulates adaptive immune responses \[[@b40-medscimonit-26-e923087]\].

Finally, the PPI screened 10 proteins closely related to TBX21. Chemokines CXCR3 transcription factor STAT4 and T-bet have been reported to control the differentiation of Th0 to Th1 cells \[[@b41-medscimonit-26-e923087],[@b42-medscimonit-26-e923087]\]. Th1 cells secrete IFNG and IL-2, which activates STAT1 and JAK1/JAK2 signaling pathways, and positively regulates TBX21 expression \[[@b43-medscimonit-26-e923087]\]. Transcription factor GATA-3 is required in the differentiation of Th2 cells \[[@b44-medscimonit-26-e923087]\]. Activated Th2 cells produce IL-4, which inhibits TBX21 expression. RUNX3 and FOXP3 upregulate the expression of T (Treg) cells and downregulate the immune response \[[@b45-medscimonit-26-e923087]\]. IL-17A is a characteristic cytokine produced by T-helper cells (Th17 cells) \[[@b46-medscimonit-26-e923087]\]. IFNG and IL-4 inhibit Th17 differentiation. All the aforementioned indicates that TBX21 can inhibit occurrence and progression of SKCM by controlling various signaling pathways and proteins. ITK is an important protein, controlling cell growth and differentiation \[[@b47-medscimonit-26-e923087]\].

In a recent study \[[@b48-medscimonit-26-e923087]\], RNA-Seq was used to analyze transcriptome data of 41 advanced SKCM patients who received anti-PD-1 therapy. The results suggest that biopsy samples from patients responding to PD-1 blockade show higher expression of TBX21. Thus, TBX21 might be used as a prognostic biomarker for the effect of SKCM on immune checkpoint inhibitors. More preclinical and clinical studies are needed to confirm and explore these underlying mechanisms, which we plan to be the focus of our future research.

In this work, we analyzed the association between the expression of individual TBX21 genes and overall survival in SKCM patients. Furthermore, we investigated the potential mechanism of TBX21 genes in SKCM patient prognosis through the GSEA database. In the future, we plan to carry out more in-depth and detailed experimental research to verify these study findings.

Conclusions
===========

This study suggests that TBX21 is overexpressed in SKCM, and it can inhibit SKCM development through multiple signaling pathways and proteins. TBX21 might be a promising prognostic biomarker for SKCM.

**Conflict of interests**

None.

**Source of support:** This work was supported by the Jiangsu Provincial Medical Innovation Team (grant numbers CXTDA2017034) and Scientific Research Project of Jiangsu Health Committee (grant numbers H2018116)

![Anatomical profile of TBX21 expression in normal human tissues (**A**) Female; (**B**) Male; TBX21 expression level gradually increased from light to dark in the picture, value=log(x+1,2), x is the specific expression of TBX21 in each tissue.](medscimonit-26-e923087-g001){#f1-medscimonit-26-e923087}

![TBX21 is expressed and distributed in normal human tissues and organs. (**A**) Box plot; (**B**) gender difference box plot; green for female, red for male. \* *P*\<0.05; \*\* *P*\<0.01; \*\*\* *P*\<0.001).](medscimonit-26-e923087-g002){#f2-medscimonit-26-e923087}

![Differential expression of TBX21 in normal skin and skin cutaneous melanoma tissues (*P*\<0.001).](medscimonit-26-e923087-g003){#f3-medscimonit-26-e923087}

![Relationship between TBX21 expression and clinical pathology. (**A**) Age. (**B**) Gender. (**C**) Clinical stage. (**D**) T stage. TBX21 expression was statistically significant during clinical stage and T stage (clinical stage: *P*\<0.001; T stage: *P*\<0.01). (**E**) Distant metastasis. (**F**) Lymph node metastasis.](medscimonit-26-e923087-g004){#f4-medscimonit-26-e923087}

![Effect of TBX21 expression on survival of skin cutaneous melanoma patients.](medscimonit-26-e923087-g005){#f5-medscimonit-26-e923087}

![Forest map of univariate (**A**) and multivariate (**B**) Cox analysis.](medscimonit-26-e923087-g006){#f6-medscimonit-26-e923087}

![Enrichment plots from gene set enrichment analysis (GSEA).](medscimonit-26-e923087-g007){#f7-medscimonit-26-e923087}

![Protein-protein interaction network. Network nodes represent proteins, content of node shows 3-dimensional structure of protein, edges represent protein-protein associations.](medscimonit-26-e923087-g008){#f8-medscimonit-26-e923087}

###### 

Clinical features of SKCM patients in TCGA database.

  Clinical characteristics   Total (445)   Percent (%)   
  -------------------------- ------------- ------------- -------
  Age at diagnosis (years)   \<58          217           48.76
  ≥58                        228           51.24         
  Gender                     Female        168           37.75
  Male                       277           62.25         
  Fustat                     Live          207           47.09
  Death                      238           52.91         
  Clinical stage             0             6             1.49
  I                          77            19.15         
  II                         130           32.34         
  III                        169           42.04         
  IV                         20            4.98          
  T stage                    Tis           7             1.74
  T0                         23            5.72          
  T1                         66            16.42         
  T2                         76            18.91         
  T3                         88            21.89         
  T4                         142           35.32         
  Distant metastasis         Negative      400           95.01
  Positive                   21            4.99          
  Lymph nodes                Negative      221           55.67
  Positive                   1             73            18.39
  2--3                       49            12.34         
  ≥4                         54            13.60         

SKCM -- skin cutaneous melanoma; TCGA -- The Cancer Genome Atlas. The median age at diagnosis was 58 years old.

###### 

Logistic regression analysis of the relationship between TBX21 expression and clinical factors.

  Clinical factors     Total (N)           OR (95% CI)               *P*-value                 
  -------------------- ------------------- ------------------------- ------------------------- ------------
  Age (years)          ≥58 *vs.* \<58      445                       0.9221 (0.6349--1.3386)   0.6697
  Gender               Male *vs.* Female   445                       0.7841 (0.5358--1.1456)   0.2093
  Stage                II *vs.* I          216                       0.4567 (0.2570--0.8031)   **0.0069**
  III *vs.* I          246                 0.8784 (0.5062--1.5138)   0.6419                    
  IV *vs.* I           99                  0.9455 (0.3694--2.4707)   0.9071                    
  T stage              T2 *vs.* T1         119                       0.4643 (0.2053--1.0122)   0.0581
  T3 *vs.* T1          131                 0.5306 (0.2383--1.1380)   0.1101                    
  T4 *vs.* T1          193                 0.3469 (0.1624--0.7089)   **0.0046**                
  Lymph nodes          N1 *vs.* N0         308                       1.0320 (0.6104--1.7424)   0.9062
  N2 *vs.* N0          283                 1.3369 (0.7214--2.5003)   0.3577                    
  N3 *vs.* N0          288                 1.3616 (0.7526--2.4855)   0.3092                    
  Distant metastasis   M1 *vs.* M0         440                       1.1932 (0.5218--2.7760)   0.6749

TBX21 -- T-box transcription factor protein 21; OR -- odds ratio; CI -- confidence interval. *P*\<0.05 was considered statistically significant, and *P*-value less than 0.05 in the table are shown in bold; the median age at diagnosis was 58 years old.

###### 

Univariate and multivariate Cox analysis of clinical factors and overall survival in SKCM patients.

  Clinical factors   Univariate analysis       Multivariate analysis                             
  ------------------ ------------------------- ----------------------- ------------------------- ------------
  Age                1.0193 (1.0084--1.0302)   **0.0005**              1.0133 (1.0022--1.0245)   **0.0183**
  Gender             1.0291 (0.7378--1.4355)   0.8657                  1.0430 (0.7438--1.4624)   0.8073
  Stage              1.3961 (1.1673--1.6699)   **0.0003**              1.0110 (0.7896--1.2945)   0.9311
  T stage            1.3380 (1.1730--1.5261)   \<0.0001                1.3017 (1.1350--1.4929)   **0.0002**
  M stage            1.7568 (0.7174--4.3020)   0.2175                  1.4131 (0.5433--3.6751)   0.4783
  N stage            1.4202 (1.2137--1.6620)   \<0.0001                1.4847 (1.1913--1.8504)   **0.0004**
  TBX21              0.6911 (0.5745--0.8315)   \<0.0001                0.7265 (0.6058--0.8713)   **0.0006**

HR -- hazard ratio; CI -- confidence interval; SKCM -- skin cutaneous melanoma *P*\<0.05 was statistically significant, and *P*-value less than 0.05 in the table are shown in bold.

###### 

Gene set enrichment analysis.

  Name                                             NES      NOM *P*-val   FDR *q*-val
  ------------------------------------------------ -------- ------------- -------------
  KEGG_Chemokine_Signaling_Pathway                 2.7256   \<0.001       \<0.001
  KEGG_Cytokine_Cytokine_Receptor_Interaction      2.6925   \<0.001       \<0.001
  KEGG_Natural_Killer_Cell_Mediated_Cytotoxicity   2.6638   \<0.001       \<0.001
  KEGG_T\_Cell_Receptor_Signaling_Pathway          2.5619   \<0.001       \<0.001
  KEGG_JAK_STAT_Signaling_Pathway                  2.5563   \<0.001       \<0.001
  KEGG_TOLL_Like_Receptor_Signaling_Pathway        2.5174   \<0.001       \<0.001
  KEGG_Apoptosis                                   2.4450   \<0.001       \<0.001
  KEGG_B\_Cell_Receptor_Signaling_Pathway          2.4338   \<0.001       \<0.001
  KEGG_MAPK_Signaling_Pathway                      1.8407   \<0.001       \<0.05

NES -- normalized enrichment score; NOM *P*-val -- nominal *P*-value; FDR q-val -- false discovery rate q-value; KEGG -- Kyoto Encyclopedia of Genes and Genomes. Gene sets with NOM *P*-val \<0.05 and FDR q-val \<0.25 are considered as significant.
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